请求参数
此 API 接口支持的参数列表
| 名称 | 类型 | 示例 | 描述 |
|---|---|---|---|
必填 | string | 284929245a22a8a9e2ed5ee82ae52250 | 药物交易ID,通过[B045]药物交易检索接口获取 |
响应结构
API 响应数据的结构说明
| 字段名 | 类型 | 示例 | 描述 |
|---|---|---|---|
data | object | - | 响应数据 |
drug | array | [
{
"drug_id": "81364d1ace044fdc8af8f60026eb2c7b",
"display_name": [
{
"lang": "EN",
"name": "Ciltacabtagene autoleucel"
},
{
"lang": "CN",
"name": "西达基奥仑赛"
}
]
}
] | 药物,引用“CommonDrug” |
drug_id | string | e82b83b42eba4e5ea3f26f8e06081a5a | 药物ID |
display_name | array | [
{
"lang": "EN",
"name": "Ranibizumab (Genentech)"
},
{
"lang": "CN",
"name": "雷珠单抗"
}
] | 药物名称,引用“CommonName” |
lang | string | EN | 语言 |
name | string | Ranibizumab (Genentech) | 药物、靶点、机构、适应症、国家/地区、字典、作用机制 名称 |
target | array | [
{
"target_id": "e49efee164e537c2a4ba9cec109e0adb",
"short_name": [
{
"lang": "EN",
"name": "BCMA"
}
],
"display_name": [
{
"lang": "EN",
"name": "B-cell maturation protein"
},
{
"lang": "CN",
"name": "B细胞成熟蛋白"
}
]
}
] | 靶点,引用“CommonTarget” |
target_id | string | 1c2067e5ab054a8995f73efcfcf56207 | 靶点ID |
short_name | array | [
{
"lang": "EN",
"name": "VEGF"
}
] | 靶点简称,引用“CommonName” |
display_name | array | [
{
"lang": "EN",
"name": "Vascular endothelial growth factor"
},
{
"lang": "CN",
"name": "血管内皮生长因子"
}
] | 靶点全称,引用“CommonName” |
deal_id | string | 284929245a22a8a9e2ed5ee82ae52250 | 药物交易ID |
partner | array | [
{
"display_name": [
{
"lang": "EN",
"name": "Janssen Biotech, Inc."
},
{
"lang": "CN",
"name": "森托克奧素生物技術產品有限合夥事業"
}
],
"organization_id": "ee3f62ab873c539d75e06f49cc09d7fc"
}
] | 受让方,引用“CommonOrganization” |
display_name | array | [
{
"lang": "EN",
"name": "Roche Holding AG"
},
{
"lang": "CN",
"name": "罗氏"
}
] | 机构名称,引用“CommonName” |
organization_id | string | 87bfaf037f8e60c9e25595cd98bb27e4 | 机构ID |
deal_time | integer<int64> | 1513814400000 | 交易时间 |
deal_type | array | [
{
"display_name": [
{
"lang": "EN",
"name": "License"
},
{
"lang": "CN",
"name": "许可"
}
],
"normalized_id": "c6bb6fa84d924b0cabd8f5dd2af17708"
}
] | 交易类型,引用“CommonDictionary” |
display_name | array | [
{
"lang": "EN",
"name": "Autologous CAR-T"
},
{
"lang": "CN",
"name": "自体CAR-T"
}
] | 字典名称 |
normalized_id | string | 2fbfdb3e92d942c48cbb0adb79f23526 | 字典ID |
drug_type | array | [
{
"display_name": [
{
"lang": "EN",
"name": "Autologous CAR-T"
},
{
"lang": "CN",
"name": "自体CAR-T"
}
],
"normalized_id": "2fbfdb3e92d942c48cbb0adb79f23526"
}
] | 药物类型,引用“CommonDictionary” |
principle | array | [
{
"display_name": [
{
"lang": "EN",
"name": "Legend Biotech USA, Inc."
}
],
"organization_id": "336e7d3b6f91616c632bc60c40a434de"
},
{
"display_name": [
{
"lang": "EN",
"name": "Nanjing Legend Biotech Co., Ltd."
},
{
"lang": "CN",
"name": "南京传奇生物科技有限公司"
}
],
"organization_id": "a22fd154855c015ed283545df379f0de"
}
] | 转让方,引用“CommonOrganization” |
deal_title | string | Janssen Enters Worldwide Collaboration and License Agreement with Chinese Company Legend Biotech to Develop Investigational CAR-T Anti-Cancer Therapy | 交易名称 |
source_url | string | https://pipelinereview.com/index.php/2017122266940/More-News/Janssen-Enters-Worldwide-Collaboration-and-License-Agreement-with-Chinese-Company-Legend-Biotech-to-Develop-Investigational-CAR-T-Anti-Cancer-Therapy.html | 新闻链接 |
deal_status | object | {
"display_name": [
{
"lang": "EN",
"name": "Active"
},
{
"lang": "CN",
"name": "进行中"
}
],
"normalized_id": "4403ccfb0e0d46b7bc86e3d14b8259e0"
} | 交易状态,引用“CommonDictionary” |
deal_total_value | object | {
"value": "Undisclosed"
} | 总金额,引用“MoneyItem” |
unit | string | million dollar | 交易单位, 枚举值:million dollar。金额未披漏时,返回为空。 |
value | string | 5000 | 交易金额,未披漏则返回“Undisclosed” |
territory_excluded | array | [
{
"country_id": "676de5ba-893a-36bb-8683-c93306aaf769",
"alpha2_code": "JP",
"display_name": [
{
"lang": "EN",
"name": "Japan"
},
{
"lang": "CN",
"name": "日本"
}
]
}
] | 权益地区(不包含),引用“CommonCountry” |
country_id | string | 676de5ba-893a-36bb-8683-c93306aaf769 | 国家地区ID |
alpha2_code | string | US | 国家编码 |
display_name | array | [
{
"lang": "EN",
"name": "United States"
},
{
"lang": "CN",
"name": "美国"
}
] | 国家地区名称 |
territory_included | array | [
{
"country_id": "4cc6684d-f7b4-392b-9dec-6fce3264fac8",
"display_name": [
{
"lang": "EN",
"name": "Global"
},
{
"lang": "CN",
"name": "全球"
}
]
}
] | 权益地区(包含),引用“CommonCountry” |
deal_upfront_payment | object | {
"unit": "million dollars",
"value": "350.00"
} | 首付款,引用“MoneyItem” |
deal_milestone_payment | object | {
"value": "Undisclosed"
} | 里程碑,引用“MoneyItem” |
status必填 | boolean | false | 状态 |
error_msg | string | The request parameter format is incorrect! | 错误信息 |
error_code必填 | integer | 0 | 错误代码 |
成功响应示例
成功调用 API 的响应示例
JSON
{
"data": {
"drug": [
{
"drug_id": "e82b83b42eba4e5ea3f26f8e06081a5a",
"display_name": [
{
"lang": "EN",
"name": "Ranibizumab (Genentech)"
}
]
}
],
"target": [
{
"target_id": "1c2067e5ab054a8995f73efcfcf56207",
"short_name": [
{
"lang": "EN",
"name": "Ranibizumab (Genentech)"
}
],
"display_name": [
{
"lang": "EN",
"name": "Ranibizumab (Genentech)"
}
]
}
],
"deal_id": "284929245a22a8a9e2ed5ee82ae52250",
"partner": [
{
"display_name": [
{
"lang": "EN",
"name": "Ranibizumab (Genentech)"
}
],
"organization_id": "87bfaf037f8e60c9e25595cd98bb27e4"
}
],
"deal_time": 1513814400000,
"deal_type": [
{
"display_name": [
{
"lang": "EN",
"name": "Ranibizumab (Genentech)"
}
],
"normalized_id": "2fbfdb3e92d942c48cbb0adb79f23526"
}
],
"drug_type": [
{
"display_name": [
{
"lang": "EN",
"name": "Ranibizumab (Genentech)"
}
],
"normalized_id": "2fbfdb3e92d942c48cbb0adb79f23526"
}
],
"principle": [
{
"display_name": [
{
"lang": "EN",
"name": "Ranibizumab (Genentech)"
}
],
"organization_id": "87bfaf037f8e60c9e25595cd98bb27e4"
}
],
"deal_title": "Janssen Enters Worldwide Collaboration and License Agreement with Chinese Company Legend Biotech to Develop Investigational CAR-T Anti-Cancer Therapy",
"source_url": "https://pipelinereview.com/index.php/2017122266940/More-News/Janssen-Enters-Worldwide-Collaboration-and-License-Agreement-with-Chinese-Company-Legend-Biotech-to-Develop-Investigational-CAR-T-Anti-Cancer-Therapy.html",
"deal_status": {
"display_name": [
{
"lang": "EN",
"name": "Ranibizumab (Genentech)"
}
],
"normalized_id": "2fbfdb3e92d942c48cbb0adb79f23526"
},
"deal_total_value": {
"unit": "million dollar",
"value": 5000
},
"territory_excluded": [
{
"country_id": "676de5ba-893a-36bb-8683-c93306aaf769",
"alpha2_code": "US",
"display_name": [
{
"lang": "EN",
"name": "Ranibizumab (Genentech)"
}
]
}
],
"territory_included": [
{
"country_id": "676de5ba-893a-36bb-8683-c93306aaf769",
"alpha2_code": "US",
"display_name": [
{
"lang": "EN",
"name": "Ranibizumab (Genentech)"
}
]
}
],
"deal_upfront_payment": {
"unit": "million dollar",
"value": 5000
},
"deal_milestone_payment": {
"unit": "million dollar",
"value": 5000
}
},
"status": true,
"error_code": 0
}错误码
此接口可能返回的错误码列表
业务错误码
| 错误码 | 描述 |
|---|---|
68300004 | 请求参数异常! |
68300005 | 查询Api失败! |
68300006 | 解析基本存取错误! |
68300007 | 存在错误的请求! |
68300008 | 服务中断异常,请稍后再试! |
68300010 | 文件不符合上传规范! |
平台错误码
| 错误码 | 描述 |
|---|---|
67200001 | API整体限流错误! |
67200002 | 用户调用请求限流限制错误! |
67200003 | 申请token的key和secret不正确或者状态错误! |
67200004 | 无权限或该接口的套餐已超过系统设置的上限! |
67200005 | 账户余额不足,调用失败! |
67200006 | 客户端已过期,调用失败! |
67200007 | 超过调用额度,调用失败! |
HTTP 状态码
| 状态码 | 描述 |
|---|---|
0 | 请求成功 |
401 | Unauthorized |
403 | Forbidden |
404 | Not Found |
性能指标
此接口的预期性能特征
正常响应时间
5000 ms
最大响应时间
10000 ms